Key Takeaways J&J, Novartis, and Roche kicked off Q2 with beats, boosting guidance on solid drug sales and strong demand.Merck, AstraZeneca, and AbbVie may see Q2 gains from rising sales of cancer and immunology drugs.MRNA's Q2 sales likely leaned on Spikevax, with focus shifting to pipeline updates amid fading COVID demand.The second-quarter 2025 reporting cycle for the Medical sector is about to pick up pace this week, as most firms are slated to share their earnings results over the next two weeks. The s ...